BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9085343)

  • 1. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with sotalol in the treatment of cardiac arrhythmias.
    Kirschenbaum HL; Rosenberg JM
    Clin Ther; 1994; 16(3):346-64. PubMed ID: 7923303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination anti-arrhythmic drug therapy].
    Lüderitz B; Jung W; Manz M
    Z Kardiol; 1992; 81 Suppl 4():157-61. PubMed ID: 1283933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
    Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
    Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation: rate control often better than rhythm control.
    Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2001 Dec; 21(12):1514-29. PubMed ID: 11765303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiarrhythmic agents: current situation].
    Bonhorst D
    Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.